Abstract |
Cefmenoxime, a new semisynthetic cephalosporin, was evaluated in vitro and in vivo in comparison with penicillin G against a type III group B streptococcal strain. In vitro, the minimal inhibitory and minimal bactericidal concentrations of the two drugs were very close (less than or equal to 2 dilutions). In-vivo studies using experimental bacteraemia and meningitis in newborn rats revealed that despite similar drug levels, cefmenoxime had significantly greater bactericidal titres in blood at 6-7 h after administration and bacterial clearance from blood was significantly faster with cefmenoxime than with penicillin G at the end of one day of treatment. In addition, all animals with cefmenoxime therapy had bactericidal titres in cerebrospinal fluid greater than or equal to 1:8 at 1-2 h after administration, whereas most (67%) animals receiving penicillin G had titres less than 1:8. However, overall efficacy of cefmenoxime was similar to that of penicillin G. These findings suggest that cefmenoxime may be an effective alternative against group B streptococcal infection.
|
Authors | K S Kim |
Journal | The Journal of antimicrobial chemotherapy
(J Antimicrob Chemother)
Vol. 17
Issue 2
Pg. 239-44
(Feb 1986)
ISSN: 0305-7453 [Print] England |
PMID | 3516964
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
- Cefmenoxime
- Cefotaxime
- Penicillin G
|
Topics |
- Animals
- Cefmenoxime
- Cefotaxime
(analogs & derivatives, metabolism, therapeutic use)
- Meningitis, Pneumococcal
(cerebrospinal fluid, drug therapy)
- Microbial Sensitivity Tests
- Penicillin G
(therapeutic use)
- Rats
- Sepsis
(drug therapy)
- Streptococcal Infections
(drug therapy)
- Streptococcus agalactiae
(drug effects)
|